Accelerating innovative medicines in times of change

Scripps Research President and CEO Peter Schultz, PhD, discusses how the nonprofit biomedical institute has expanded the bounds of academic research to transform drug development. Using state-of-the-art drug discovery methods and new approaches to translational medicine, the institute is quickly turning new scientific insights into effective drugs. Schultz also will share updates on Scripps Research’s COVID-19 programs and its growing drug pipeline, which encompasses new treatments for cancer, neurodegenerative disease, osteoarthritis and more.